Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET

Company Participants

Eric McIntyre - Head, IR

Todd Watanabe - President, CEO & Director

Kenneth Lock - Chief Commercial Officer

Patrick Burnett - SVP & Chief Medical Officer

Scott Burrows - CFO & Principal Accounting Officer

Conference Call Participants

Kenneth Cacciatore - Cowen

Vikram Purohit - Morgan Stanley

Louise Chen - Cantor Fitzgerald

Serge Belanger - Needham & Company

Seamus Fernandez - Guggenheim Securities

Gregory Fraser - Truist Securities

Uy Ear - Mizuho Group

Operator

Good day, and thank you for standing by. Welcome to the Arcutis Biotherapeutics, Inc. Q3 2022 Earnings Conference Call. [Operator Instructions].

I would now like to hand over the conference to your first speaker today, Eric McIntyre, Head of Investor Relations. Please go ahead.

Eric McIntyre

Thank you, Chris. Good afternoon, everyone, and thank you for joining Arcutis' first quarterly earnings call. On today's call, we have Frank Watanabe, President and CEO; Scott Burrows, Chief Financial Officer; Ken Lock, Chief Commercial Officer; and Patrick Burnett, Chief Medical Officer.

During this call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. We will then go to Q&A after our prepared remarks.

With that, I'll hand the call to Frank.

Todd Watanabe

Thanks, Eric. Yes, I'll just add my thanks as well for joining us for our very first earnings call. Today, we're going to be talking about our third quarter performance as well as providing some general updates to you all on our business and the progress that we've made so far this year. So you should have access to the deck on our investor webpage. I'm on Slide 5 to start with.

We've been talking all year along about 2022 being a transformational year for Arcutis. We've already delivered on a number of very important catalysts and we've got one very big one coming up just ahead of us. As you look at this slide, I think it's really remarkable, everything that our organization has been able to accomplish just in the last 3 quarters -- and last 3 months, excuse me, last quarter.

Obviously, first and foremost, was the launch of ZORYVE 0.3% cream for plaque psoriasis. This is a massive step forward for us in fulfilling our mission of helping patients and bringing meaningful innovation to dermatology. The launch continues to progress really well and momentum is building. And we've got the right team. We're confident we have the right strategy and we certainly know that we've got the right product profile in ZORYVE continue to prove all of that and then to seek out additional reformat indications as we've talked about before, seborrheic dermatitis, atopic dermatitis and scalp psoriasis. And Ken is going to be talking a little bit more about the launch in just a few minutes.